New Developments in the Treatment of Alzheimer’s Disease

First identified as a disease process in the early 1900s, today Alzheimer’s disease (AD) looms as a public health crisis. In 2000, an estimated 4.5 million persons in the United States had mild, moderate, or severe AD; this figure could grow to 13.2 million by 2050.1 Peter V. Rabins, MD, MPH, brought together a group of experts to discuss ways to better diagnose and more effectively treat this rapidly growing population.

Progression From Mild Cognitive Impairment to Alzheimer’s Disease

Prevalence
As the population ages and survival rates increase for patients with AD, not only will the number of persons with the disease increase rapidly, said Neill Graff-Radford, MB BCh, FRCP, but also the age distribution of persons with AD will change. In 2000, the majority of persons with AD were between the ages of 75 and 84 years; by 2050, persons with AD in this age group could double from 2.4 million to 4.8 million.1 However, the number of individuals with AD who are aged 85 years or older is expected to more than quadruple, from 1.8 million to 8 million.1

The prevalence of AD increases with age, and the proportion of patients with severe AD as opposed to mild or moderate AD also increases with age. In 2000, AD was present in about 5% of those aged 65 to 74 years, almost 20% of those aged 75 to 84 years, and more than 45% of those aged 85 years or older.1

The opinions expressed herein are those of the faculty and do not necessarily reflect the views of the CME provider and publisher or the commercial supporter.

Financial disclosure: Dr. Rabins is a consultant for Merck; is a consultant for and/or has received lecture fees from Abbott, Dakim, Eisai, Forest, Mattel, Myriad Genetics, Novartis, Ortho-McNeil, Pfizer, Radica, Siemens, and VerusMed; has received stock options from Dakim; and is among the inventors of and receives royalties on U.S. patent no. 6,274,119, “Methods for Labeling Beta-Amyloid Plaques and Neurofibrillary Tangles,” which was licensed to Siemens. Dr. Yaari is a consultant for Merck.

© Copyright 2009 Physicians Postgraduate Press, Inc.
between 58% and 79%. Genetic factors were similar for men and women. Thus, prevalence and heritability data indicate that age and genetics are the crucial risk factors for AD, said Dr. Graff-Radford.

**Mild Cognitive Impairment**

Mild cognitive impairment (MCI) is the pathological condition that lies along a continuum between the cognitive changes seen in the normal aging process and early dementia. A set of criteria for diagnosing MCI has been developed. The first criterion is a subjective cognitive complaint from the patient, preferably corroborated by an informant. Second, neuropsychological testing should confirm that the patient has cognitive impairment relative to his or her age. Third, despite cognitive problems, the patient’s general intellectual functioning should be near normal. The last criterion is that the patient is able to function normally. Based on these criteria and the *Diagnostic and Statistical Manual of Mental Disorders* definition of dementia, the physician may conclude that the patient does not meet the criteria for dementia.

Subtypes of MCI have been identified (Figure 1). If memory impairment is the main cognitive problem, the patient is considered to have amnestic MCI. Nonamnestic MCI could mean the patient’s main cognitive problem is with language, visuospatial skills, executive function, or attention. If only 1 cognitive domain is affected (whether it is memory or not), then the person has single domain MCI. If the person has several areas of cognitive impairment, he or she is considered to have multiple domain MCI.

The MCI subtypes may have different etiologies, which can help to determine the eventual outcome for the patient (Figure 2). For example, for amnestic MCI, etiologies include AD, vascular cognitive impairment, or depression, and, for nonamnestic MCI, the etiology may be frontotemporal dementia, Lewy body dementia, or vascular cognitive impairment.

In a population-based study of 1,704 individuals with a median age of 79 years, the prevalence rate of MCI was 17%. Among those 70 to 74 years, 9% had MCI, and among those 85 to 89 years, 25% had MCI. Three fourths had amnestic MCI. More men than women had MCI, and the rate was also higher in people with fewer years of education.

---

**Figure 1. Flowchart for Diagnosis of Mild Cognitive Impairment (MCI) Subtypes**

![Flowchart](Image)

*Reprinted with permission from Petersen and Morris.*
Petersen et al12 studied patients with MCI and healthy control subjects. During 4 years of follow-up, 12% of patients diagnosed with MCI at baseline converted to AD each year. During 10 years of follow-up, healthy control subjects developed MCI or AD at a rate of 1% to 2% per year. Identifying MCI in a patient could be useful as a predictor for AD and allow for earlier intervention in the disease process.

Cerebrospinal Fluid Biomarkers for AD in MCI Patients

One way to predict whether MCI will progress to AD is to study biomarkers in the patient’s cerebrospinal fluid (CSF). Riemenschneider et al13 found that patients with MCI who progressed to probable AD had higher CSF tau protein levels and lower Aβ42 protein levels than patients with stable MCI. Dr. Graff-Radford added that patients with MCI in Europe often undergo a spinal tap to determine their tau and Aβ42 levels, while patients with MCI in the United States are more commonly followed clinically.

Fagan et al14 found that, whether individuals had dementia or not, the level of CSF Aβ42 corresponded with the presence or absence of amyloid deposits in the brain. Together, the presence of brain amyloid deposits (determined by imaging tests) and reduced levels of CSF Aβ42 can help to confirm the clinical diagnosis of MCI related to AD pathology and can also possibly be used to predict future MCI in cognitively normal individuals or progression to AD in people with MCI.

Plasma Biomarkers for AD in MCI Patients

Using the comparison of checking cholesterol levels to predict heart disease, Dr. Graff-Radford reported on a study15 that he and his colleagues conducted to investigate whether plasma levels of Aβ40 and Aβ42 could identify cognitively normal persons at risk for MCI or AD. The study found that participants with plasma ratios of Aβ42/Aβ40 in the lowest quartile had 3 times the risk for developing MCI or AD compared to those in the highest quartile. These findings were similar to those reported by van Oijen et al.16 They found that those in the lowest tertile of the Aβ42/Aβ40 ratio had a 10 times greater chance of developing dementia. Another study17 has shown that the same low plasma ratio of Aβ42/Aβ40 in subjects with depression was associated with greater impairment in memory, possibly representing a subtype of depression that could be a manifestation of prodromal AD.

Searching for a molecular test for AD, Ray et al18 identified 18 signaling proteins found in blood plasma that could distinguish normal controls from individuals with AD with almost 90% accuracy. These blood proteins also correctly predicted those individuals with MCI who would later develop AD.

Conclusion

The prevalence of AD is growing as the population ages. An understanding of the biomarkers that predict risk for developing AD, concluded Dr. Graff-Radford, may enable studies of how to delay or prevent the disease.

Advances in Neuroimaging and Other Diagnostic Strategies

Accurately diagnosing AD in clinical practice remains challenging. Gary W. Small, MD, cited a literature review19 of studies that addressed the diagnostic accuracy of current sets of criteria. Criteria for dementia of the Alzheimer’s type in the Diagnostic and Statistical Manual of Mental Disorders, Third Edition, and criteria for probable AD from the National Institute of Neurological and Communicative Disorders and AD and Related Disorders Association averaged a good sensitivity of 81%, with 70% specificity. Criteria for a “possible” AD diagnosis had a high sensitivity of 93%, with 48% specificity. With fairly low specificity, room for improvement exists, said Dr. Small.

Use of imaging tools can increase the diagnostic accuracy of AD. The Alzheimer’s Disease Neuroimaging Initiative20 now provides information to clinicians on which neuroimaging
MRI Analysis of Neuropsychological Domains

Table 1. Correlations Between Neuropsychological Performance and Quantitative MRI Analysis of Neuropsychological Domains

<table>
<thead>
<tr>
<th>Neuropsychological Domain</th>
<th>VBR</th>
<th>Hippocampal Volume</th>
<th>Temporal Horn Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>Immediate memory</td>
<td>-27**</td>
<td>.22*</td>
<td>-28†</td>
</tr>
<tr>
<td>Delayed memory</td>
<td>-24**</td>
<td>.26**</td>
<td>-22*</td>
</tr>
<tr>
<td>Visual/spatial/praxis</td>
<td>-19*</td>
<td>.03</td>
<td>-19*</td>
</tr>
<tr>
<td>Language</td>
<td>-32†</td>
<td>.06</td>
<td>-39†</td>
</tr>
<tr>
<td>Executive</td>
<td>-26**</td>
<td>-.03</td>
<td>-19*</td>
</tr>
<tr>
<td>Intelligence</td>
<td>-21*</td>
<td>.21*</td>
<td>.11</td>
</tr>
</tbody>
</table>

*Reprinted with permission from Bigler et al. 30
*P = .05
**P = .01
†Significant after Bonferroni correction, P = .008.
Abbreviation: VBR = ventricle-to-brain ratio.

Structural Imaging Tools

In clinical practice today, magnetic resonance imaging (MRI) and computed tomography scans are used to rule out space-occupying lesions, tumors, strokes, normal pressure hydrocephalus, and so forth, said Dr. Small. However, these structural imaging tools can also be used to detect tissue atrophy to rule in a diagnosis of AD.

Generally, atrophy in the medial temporal regions is greater in patients with AD compared with controls. Frisoni et al21 demonstrated that high-resolution MRI can pinpoint in vivo the regions and subregions that are informative about diagnosis. Their imaging of patients with mild-to-moderate AD showed tissue loss of 20% or more in the hippocampal formation. Another study25 using MRI has shown that patients with AD had 10% to 15% greater cortical atrophy than patients with amnestic MCI, making MRI a useful technique for differentiating these 2 groups during diagnosis.

Functional Imaging Tools

Different types of imaging can assist clinicians with prognosis. Functional imaging tools, such as positron emission tomography (PET), can be used to predict disease progression. Metabolism throughout the cortex and deeper structures can be progressive or nonprogressive,26 and AD has a recognizable pattern of progressive hypometabolism in the temporoparietal and posterior cingulate cortices. Other progressive diseases are associated with hypometabolism in other areas of the brain. Nonprogressive patterns of metabolism may be seen with a tumor or stroke. The use of PET to view areas of hypometabolism in the brain was studied as an adjunct in the diagnosis of AD and was found to increase diagnostic accuracy by decreasing false positive and false negative diagnoses.24

Mosconi et al25 combined PET with screening for the ApoE4 genotype to improve prediction of MCI conversion to AD. They found that hypometabolism in the inferior parietal cortex predicted conversion to AD with an accuracy of 84%. In patients with the ApoE4 genotype, metabolism reductions within frontal areas such as the anterior cingulate and inferior frontal cortices increased prediction of conversion to AD to 94% accuracy.

Dr. Small also described a study26 that he and his colleagues conducted using PET in patients with normal memory to determine patterns of cognitive and metabolic decline. After 2 years, patients with one copy of the ApoE4 allele had 5% lower inferior parietal and lateral temporal metabolism and 4% lower left posterior cingulate metabolism. Amyloid senile plaques and tau NFTs are the pathological hallmarks of AD; they accumulate in cortical regions of the brain in people with MCI who are at risk for AD. Identifying the patterns of plaques and tangles in vivo can facilitate early diagnosis. Small-molecule probes used with PET imaging in humans have shown differences in the areas of the brain known to collect plaques and tangles between patients with AD, those with cognitive impairment, and controls who are aging normally.27–29 As patients decline clinically, the plaque and tangle burden increases.

Neuropsychological Testing

Neuropsychological testing is often used to validate the diagnosis of AD and help differentiate MCI from AD and normal aging. A variety of cognitive functions on neuropsychological tests, such as immediate memory, have been found to correlate with various neuroimaging results, such as hippocampal volume measured by MRI, explained Dr. Small (Table 1).30

In clinical practice, these tests can be used to document and confirm cognitive deficits early in the disease or in atypical populations. Documenting specific deficits can assist in characterizing a specific dementia diagnosis and in determining the functional consequences of that diagnosis.

Neuropsychological tests can also be used to document disease progression; the rate of change in cognitive performance may predict a diagnosis up to a decade in advance.31 Computerized cognitive testing has been developed, which can improve the efficiency of testing in clinical practice; these tests can identify MCI or dementia even in patients with depression.32 Thus, neuropsychological tests can be used quantitatively and longitudinally.

Conclusion

Dr. Small ended by stating that neuroimaging increases the accuracy of clinical diagnosis in AD in several ways. Structural imaging can show hippocampal atrophy, which is accelerated in individuals with MCI and AD compared with controls. Functional imaging can reveal a characteristic pattern of parietal, temporal, and posterior cingulate hypometabolism in patients with AD. The ApoE4 allele...
further helps predict cognitive decline. Small-molecule probes hold tremendous promise in visualizing amyloid plaques and NFTs. In addition, neuro-psychological testing continues to be helpful in the diagnosis of AD and allows for monitoring of disease progression and documentation of deficits.

Current Treatments for Different Phases

The American Psychiatric Association (APA) guidelines for the treatment of AD were first published in 1997 and were updated in 2007. In 2006, the American Academy of Geriatric Psychiatry (AAGP) published a position statement on principles of care for patients with AD, and in 2001, the American Academy of Neurology (AAN) published its practice parameter for managing dementia. Dr. Rabins reviewed and compared these guidelines for the treatment of AD.

American Psychiatric Association

The APA guidelines advise that the treatment of patients with AD should be based on the results of a thorough evaluation of their medical, neurological, and psychiatric status. Medical problems that may contribute to dementia should be identified and treated.

The APA states that cholinesterase inhibitors (ie, tacrine, donepezil, rivastigmine, and galantamine) are modestly effective for treating AD symptoms. These agents and memantine, an N-methyl-d-aspartate (NMDA) antagonist, have been approved by the US Food and Drug Administration (FDA) for the treatment of different phases of AD (Table 2). Vitamin E is no longer recommended for AD by the APA. High-dose vitamin E may have cardiovascular toxicity, and trials have not supported efficacy in more than a decade. The guidelines also recommend against the use of estrogen or other hormone replacement therapy agents and against the use of nonsteroidal anti-inflammatory drugs (NSAIDs), based on both the potential for toxicity and adverse effects as well as a lack of demonstrated efficacy of either prevention or benefit once the diagnosis has been established. Evidence also does not currently support the use of ginkgo biloba, selegiline, or chelating agents.

American Association for Geriatric Psychiatry

The AAGP position statement on principles of care for patients with AD stresses that the management of vascular disease and its risk factors should be considered a part of the standard care for these patients. Care should include monitoring the patient’s blood pressure, glucose, cholesterol, and homocysteine levels. The administration of low-dose aspirin or other anticoagulation treatment should be considered for patients who have significant vascular disease.

The AAGP supports the use of cholinesterase inhibitors in the treatment of mild to moderate AD but recommends that tacrine be avoided due to its complex titration and risk of hepatic toxicity. The position statement cites better evidence for the combination of memantine with a cholinesterase inhibitor than for switching between cholinesterase inhibitors or combining 2 of them.

Dr. Rabins pointed out that the AAGP principles of care caution against doses of vitamin E above 400 IU per day. The AAGP also does not recommend using estrogen, ginkgo biloba, or NSAIDs as treatments for AD.

The AAGP guidelines give similar recommendations concerning antipsychotics as the APA. The AAGP policy statement also emphasizes caregiver support and education about patient

Table 2. Treatment Options for Alzheimer’s Disease

<table>
<thead>
<tr>
<th>Approved Indication</th>
<th>Description</th>
<th>Drug</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mild to moderate dementia of the Alzheimer’s type</td>
<td>Reversible ChEI</td>
<td>Tacrine</td>
</tr>
<tr>
<td>Mild to moderate dementia of the Alzheimer’s type</td>
<td>Reversible, selective ChEI</td>
<td>Donepezil</td>
</tr>
<tr>
<td>Mild to moderate dementia of the Alzheimer’s type</td>
<td>Reversible ChEI</td>
<td>Rivastigmine</td>
</tr>
<tr>
<td>Mild to moderate dementia of the Alzheimer’s type</td>
<td>Reversible, competitive ChEI</td>
<td>Galantamine</td>
</tr>
<tr>
<td>Moderate to severe dementia of the Alzheimer’s type</td>
<td>Noncompetitive NMDA receptor antagonist</td>
<td>Memantine</td>
</tr>
</tbody>
</table>

*Adapted with permission from Geldmacher. Abbreviations: ChEI = cholinesterase inhibitor, NMDA = N-methyl-d-aspartate.*
safety and health, problem-solving skills, long-term care planning, and re-
spite for oneself.

**American Academy of Neurology**

Because the AAN practice param-
eter is an older set of guidelines than the others, it not only supports the use of cholinesterase inhibitor medications for AD but also reports efficacy of vi-
tamin E and requests more study of selegiline, NSAIDS, and estrogen.35

Recommendations regarding antipsy-
chotic medicines and antidepressants in patients with AD are similar to those of the other 2 sets of guidelines. Care-
giver education is also recommended to delay the time to nursing home placement.

**Conclusion**

The APA guidelines, the AAGP principles of care, and the AAN prac-
tice parameter agree on many elements of treating patients with AD. Various medications are approved for the treat-
ment of different phases of AD, but nonpharmacologic interventions for both patients and caregivers are also crucial. Dr. Rabins reminded clinicians that recommendations will change as new treatments and diagnostic tests be-
come available for AD.

---

**Advances in Pharmacotherapy and Potential New Treatment Targets**

Treatments in development for AD are currently divided into the 2 major categories of symptomatic therapy and disease-modifying therapy. Symptomatic therapies do not affect the under-
lying pathological process of AD that leads to cell death, but they can pro-
vide benefit for the patient in such ar-
reas as cognition, global measures, ac-
tivities of daily living, and behavior. Disease-modifying therapies are drugs that target the pathophysiology of AD and could potentially slow or stop dis-
ease progression.37 The earlier that this type of therapy could be used in the disease process, the greater benefit it could provide to the patient. These cat-
egories are not mutually exclusive; po-
tentially, a compound could be both a symptomatic therapy and a disease-
modifying therapy.

Both symptomatic and disease-
modifying therapies are under in-
vestigation (Table 3). Investigational symptomatic therapies are mainly neurotransmitter-based interventions. Disease-modifying therapies target either the amyloid pathway or the tau pathway. Roy Yaari, MD, MAS, re-
viewed current research into new treatments for AD.

**Symptomatic Treatments**

**Cholinergic therapies.** The cholin-
ergic hypothesis is based on consider-
able evidence that central cholinergic neurotransmission plays a critical role in aspects of cognition.38 The production of choline acetyltransferase, a key enzyme in the synthesis of the neuro-
transmitter acetylcholine, is reduced in AD, which leads to less acetylcholine synthesis and, therefore, impaired cor-
tical cholinergic function.39

The hypothesis that the ameliora-
tion of cholinergic neurotransmission would result in improved cognition led to the development of the acetylcholin-
esterase inhibitors. These drugs inhibit the cholinesterase enzyme from breaking down acetylcholine, increasing both the level and the duration of action of acetylcholine. New cholines-
terase inhibitors are in development.

Additionally, research has shown that nicotinic acetylcholine receptors are lost in the hippocampus and tem-
poral and frontal cortex in patients with AD.40 In small studies, nicotine im-
proved memory, cognition, and atten-
tion in AD, while nicotinic antagonists showed the opposite effect.41 Nicotinic agonists that selectively target the central nervous system (CNS) are in development.40

**Glutamatergic therapies.** Gluta-
mate is the primary excitatory amino acid in cortical and hippocampal neu-
rons, and it plays an important role in synaptic transmission.42 Normally, it binds to a variety of receptors, result-
ing in long-term potentiation of neu-
ronal activity that may be critical in memory and learning. Excessive activ-
ation of these receptors by glutamate can destroy cells through what is called excitotoxicity,43 so it is possible that glutamatergic dysregulation plays a role in AD. The NMDA receptors are a subtype of glutamate ionotropic recep-
tors, and NMDA receptor antagonists are in development; memantine is the only one approved at this time.

**Histamine modulators.** Histamine, a neurotransmitter in the brain, may play a role in the control of cognition and is decreased in the brains of pa-
tients with AD.44 Therefore, drugs that increase histaminergic activity may improve cognition in AD. Preclinical tests of H3 receptor antagonists have found improvement in attention and memory tasks, while H3 receptor ago-

nons have had impairing effects on cognition.45

One particular histamine modulator, the antihistamine dimebon (dimebolin hydrochloride), is currently in phase III development. A 6-month random-
ized, double-blind, placebo-controlled phase II trial showed significant benefit of dimebon over placebo (P < .0001) on cognitive measures in patients with mild to moderate AD (Figure 3).46 This compound is thought to inhibit neuronal death by mitochon-
drial-mediated inhibition of apoptosis47 and to contain properties that inhibit acetylcholine esterases and NMDA receptors.48

**Disease-Modifying Treatments**

**Amyloid-based interventions.** Dr. Yaari explained that the amyloid cascade hypothesis posits that one cause of AD, as mentioned by Dr. Graff-Radford, is the accumulation, or decreased clearance, of Aβ from the brain. The aggregation of Aβ25 peptides into amyloid plaques is thought to interfere with cognition and lead to synaptic dysfunction and cell death and to contribute to the formulation of NFTs. Steps in this cascade could
provide targets for drug development, which Dr. Yaari described (Figure 4).49

**Immunotherapies.** Immunotherapy could target several steps in the amyloid cascade hypothesis (see Figure 4). One immunotherapy hypothesis is that immunization could clear Aβ from the brain through microglial-mediated phagocytosis.50 The “sink” hypothesis of immunotherapy holds that brain plaque clearance does not require antibody entry into the brain or a cell-mediated response but that brain Aβ can be reduced through an agent that sequesters plasma Aβ peripherally into a “sink.”51

Immunotherapies can be divided into 2 categories: active and passive.49 Active immunotherapies introduce an antigen, which is a variant of the Aβ peptide, producing an immune response against that antigen. Passive immunization delivers synthetic antibodies against the Aβ peptide into the host, facilitating an immune-mediated clearance of the antigen.

Passive immunotherapy requires less time to generate an immune reaction in the host than active immunization and also eliminates the issue of inadequate antibody response that is sometimes seen with active immunotherapy, especially in older people. However, active immunization could theoretically require a 1- or 2-time dose, whereas passive immunization would require regular administration of antibodies at fixed intervals to continue the immune response, said Dr. Yauri.

In transgenic mouse models of AD, immunotherapy has successfully cleared Aβ deposits52 and improved various cognitive deficits.53 In a human study54 using an active vaccine, 300 participants received the drug, and 59 (19.7%) developed an antibody response; however, no clinical benefit was seen on the primary outcome measures. Those who responded to the antibody showed a decrease in CSF tau. Serial MRIs showed an unexpected loss of brain volume in the individuals who were antibody responders versus the placebo patients, but the decreased brain volume was not associated with worsened cognitive performance.55 Autopsies of patients who had responded to immunization showed clearance of amyloid plaque.56

The study was prematurely terminated because 18 (6%) of the participants developed aseptic meningitis.54 Current development efforts for active immunotherapies are focusing on activating highly specific antibody responses to the Aβ antigen to minimize adverse effects.

Passive immunotherapy trials are also underway.57 Bapineuzumab, a monoclonal antibody targeting amyloid, completed a phase II study showing benefit in a subgroup of patients.58 A very large phase III study of bapineuzumab is currently underway. Human intravenous immunoglobulin, a drug that is currently available for treatment of other neurological disorders and contains Aβ antibodies, has shown positive effects in open-label pilot studies, such as reducing Aβ in the CSF and stabilizing cognitive measures.59,60

**Secretase inhibitors.** The transmembrane amyloid precursor protein (APP) is a substrate for the 3 enzymes α-, γ-, and β-secretase. Normally, APP is cleaved by α-secretase at a site that does not result in Aβ production, but, in pathological conditions, APP is cleaved initially by β-secretase and then γ-secretase, resulting in increased Aβ production (see Figure 4).

The β-secretase inhibitors are potentially more useful for AD than γ-secretase inhibitors because β-secretase inhibitors target one of the initial events in the amyloid cascade, but they tend to be large molecules, making it difficult to penetrate the blood-brain barrier. No β-secretase inhibitors have lasted beyond early clinical development.

The development of γ-secretase inhibitors is further along than that of β-secretase inhibitors. However, γ-secretase inhibitors also affect the Notch signaling protein, which is an important intermediary in cellular functions that regulate the differentiation of cells in such areas as the

---

**Table 3. Categories of Investigational Therapies**

<table>
<thead>
<tr>
<th>Symptomatic therapies</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neurotransmitter-based interventions</td>
</tr>
<tr>
<td>Cholinergic therapies</td>
</tr>
<tr>
<td>Glutamatergic therapies</td>
</tr>
<tr>
<td>Histamine modulators</td>
</tr>
<tr>
<td>Disease-modifying therapies</td>
</tr>
<tr>
<td>Amyloid-based interventions</td>
</tr>
<tr>
<td>Immunotherapy</td>
</tr>
<tr>
<td>Secretase inhibitors/modulators</td>
</tr>
<tr>
<td>Anti-aggregation agents</td>
</tr>
<tr>
<td>Tau-based interventions</td>
</tr>
</tbody>
</table>

---

**Figure 3. Effect of Dimebon on Cognition in Patients With Alzheimer’s Disease**

*Reprinted with permission from Doody et al.55
Mean change in the ADAS-cog scale from baseline to week 26. All analyses shown are intention to treat, last observation carried forward analyses. Error bars show SE. P values are shown for comparison of mean changes from baseline for dimebon versus placebo groups at week 26, for dimebon mean baseline score versus week 26 mean score, and placebo mean baseline score versus week 26 mean baseline score.

Abbreviation: ADAS-cog = Alzheimer’s disease assessment scale-cognitive subscale.
gastrointestinal tract and immune system. Therefore, current research aims at finding compounds that are specific to the γ-secretase cleavage of APP. Trials of γ-secretase inhibitors have demonstrated reduced Aβ concentration in plasma but not CSF.

**Selective Aβ42-Lowering Agents.** Selective Aβ42-lowering agents (SALAs) are NSAID analogues that allosterically modulate, instead of inhibit, γ-secretase. By altering the site of action of γ-secretase on the APP membrane (see Figure 4), SALAs promote formation of the shorter, less toxic Aβ peptides and reduce the amount of longer, more toxic Aβ1-42 peptides. These agents do not seem to affect the Notch system. One of these agents reached Phase III study but failed to show efficacy on the primary outcome measures, so development stopped.

**Anti-aggregation agents.** By binding to soluble Aβ peptides, anti-aggregation agents can prevent the downstream toxic effects of Aβ deposition (see Figure 4). A Phase II study among patients with mild to moderate AD showed that an anti-aggregation agent reduced CSF Aβ42 levels, but test results showed no significant change in cognition. A multicenter Phase III trial failed to show efficacy for cognitive improvement. Another anti-aggregate is in Phase I study.

Heavy metal ions are thought to play a role in the fibrillization of Aβ, and a heavy metal chelator could potentially reduce the polymerization of the Aβ. One agent with copper and zinc chelation properties reduced plasma Aβ but showed no clinical benefit and was associated with optic nerve damage, so development was halted. A Phase IIa study of another chelating agent showed reduced CSF (but not plasma) Aβ42 concentration and also demonstrated cognitive improvement.

Curcumin, an active ingredient in turmeric powder (giving the spice its color but not flavor), possesses antioxidant and anti-aggregation properties. Curcumin has been shown to bind to amyloid deposits in mice, reducing amyloid plaque burden and reversing some of the structural changes associated with the plaques. A 6-month pilot clinical trial did not show clinical benefit, but any protective effect of the agent may have been obscured because patients taking placebo did not show cognitive decline. Finally, colosstrim, a proline-rich polypeptide found in sheep colostrum, is thought to inhibit Aβ aggregation and has shown a stabilizing effect on cognitive function.

Other amyloid-based interventions. The receptor for advanced glycation endproducts (RAGE) enzyme is a transporter of Aβ from the periphery into the CNS. Inhibition of RAGE is being investigated as a means of blocking the transport of Aβ from the blood to the brain to lower Aβ levels in the CNS. A Phase II trial is underway.

Epidemiologic data suggest that statins may decrease the risk of dementia, possibly by upregulating α-secretase and thereby decreasing toxic Aβ42. Epidemiologic data have also suggested a reduced risk of dementia, particularly AD, with fish consumption. Docosahexaenoic acid, better known as DHA, is an omega-3 fatty acid found in fish oil and is an integral component of neural membrane phospholipids. A large multicenter Phase III study of DHA for AD is being conducted.

**Tau-based interventions.** The abnormal hyperphosphorylation of tau proteins that results in NFTs is associated with an imbalance in the activity levels of tau kinases and phosphatases. Inhibition of the kinases responsible for tau hyperphosphorylation is being pursued as a treatment strategy for treatment of AD, but development of tau-based interventions lags far behind that of amyloid-based therapies. Lithium and valproate inhibit a kinase that is involved in
tau hyperphosphorylation,\textsuperscript{80} and research is beginning to explore the viability of these agents as AD treatment. Methylthioninium chloride is an agent thought to inhibit tau aggregation,\textsuperscript{81} a phase III trial is scheduled for 2009.

**Conclusion**

Meaningful advances in the understanding of AD pathophysiology have occurred, said Dr. Yaari, and these have led to the discovery of multiple targets for the development of drugs that could potentially halt or even prevent the disease. Neurotransmitter-based therapies have been shown to improve cognition; all FDA-approved therapies that are currently available are neurotransmitter-based therapies. Amyloid-based therapies are further along in development than other therapies, although it is still unknown whether they will actually yield clinical benefits. The severity of cognitive impairment is closely related to NFTs, but the antitangle therapy pipeline is not as robust as that of the anti-amyloid pathway. Progress has been made, but continuing research is needed to develop disease modifying treatments and prevention methods for AD.

**Drug names:** donepezil (Aricept and others), rivastigmine (Exelon and others), memantine (Namenda), rivastigmine (Exelon and others), selegiline (Eldepryl, Zelapar, and others), tacrine (Cognex).

**Disclosure of off-label usage:** The chair has determined that, to the best of his knowledge, human intravenous immunoglobulin, lithium, selegiline, and valproate are not approved by the US Food and Drug Administration for the treatment of dementia and Alzheimer’s disease.

**References**